Nashville, TN - The selective COX-2 inhibitor rofecoxib (Vioxx® - Merck) has taken another knock in the ongoing saga of cardiovascular side effects, with a new study suggesting that serious cardiac ...
Solomon et al say that several biological pathways could underlie a potential association between selective COX-2 inhibitors and coronary events. For example, in rat models of hypertension, celecoxib ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
A comparison of internal company documents, data submitted by the company to the FDA, and published clinical trial results indicates that the risk-benefit profile of rofecoxib in clinical trials ...
Impact of a Higher Radiation Dose on Local Control and Survival in Breast-Conserving Therapy of Early Breast Cancer: 10-Year Results of the Randomized Boost Versus No Boost EORTC 22881-10882 Trial In ...
Merck & Co. has no plans to bring rofecoxib back to the market, despite a narrow vote by a Food and Drug Administration advisory panel saying limited distribution would be acceptable. On the second ...
Bethesda, MD (August 30, 2006) – The use of the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (Vioxx®) reduces the risk of colorectal adenomas, according to data being published in Gastroenterology, ...
Inhibition of cyclo-oxygenase 2 might slow the progression of colorectal cancer, but might also increase the risk of adverse cardiovascular events. The cyclo-oxygenase 2 inhibitor rofecoxib was ...
Laboratory and case-control studies suggest a pivotal role for the cyclooxygenase-2 (COX-2) pathway in colorectal carcinogenesis. The purpose of this study was to test whether the COX-2 inhibitor ...
NEW YORK, June 27 (Praxis Press) Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) but it is unclear whether specific COX-2 inhibitors ...
Clinical studies have failed to show convincing effects of nonsteroidal anti-inflammatory drugs (NSAIDs)—including the selective cyclo-oxygenase 2 (COX2) inhibitor rofecoxib—on the progression of ...
A comparison of internal company documents, data submitted by the company to the FDA, and published clinical trial results indicates that the risk-benefit profile of rofecoxib in clinical trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results